Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Century Therapeutics ( (IPSC) ).
Century Therapeutics announced that Bristol-Myers Squibb will terminate their collaboration agreement effective March 12, 2025, following BMS’s internal portfolio prioritization. Despite this, Century remains optimistic about the scientific progress made and plans to explore opportunities in acute myeloid leukemia and multiple myeloma, aligning with their strategic review of the pre-clinical pipeline.
More about Century Therapeutics
Century Therapeutics operates in the biotechnology industry, focusing on the development of induced pluripotent stem cell derived therapies, particularly engineered natural killer and gamma delta T cells for treating hematologic malignancies.
YTD Price Performance: -62.35%
Average Trading Volume: 496,839
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $106.3M
See more insights into IPSC stock on TipRanks’ Stock Analysis page.